Compare AstraZeneca plc (AZN) vs Byrna Technologies Inc (BYRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Byrna Technologies Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Byrna Technologies Inc trades at $4.28 (market cap $106.74M). The key difference: AstraZeneca plc is far larger — about 2324.7× Byrna Technologies Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| AZN | BYRN | |
|---|---|---|
Market Cap | $248.14B | $106.74M |
Sector | Health | Technology |
52-Week High | $209.48 | $27.63 |
52-Week Low | $147.06 | $3.18 |
Enterprise Value | $275.41B | $98.35M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
BYRN trades at $4.25, down 12.37% on the day, reflecting investor reaction to recent earnings misses and revenue declines. The stock shows a bullish technical signal with strong moving average support, but fundamentals are mixed with a negative net income margin of -3.39% and ROE of -6.3% for 2026. Recent management changes and strategic acquisitions aim to revitalize growth amid sales challenges highlighted in Q2 2026 results.
The outlook remains cautious due to execution risks in marketing turnaround and competitive pressures. Analyst consensus is 71% buy, but investors face volatility from ongoing investigations and weak quarterly performance. Upside depends on successful brand repositioning and retail expansion under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →
